MD Anderson and P-Cure partner on upright particle therapy technology

The University of Texas MD Anderson Cancer Center and P-Cure have entered a strategic partnership to evaluate a compact particle therapy platform. The system is designed to deliver both proton and helium ions from a single unit while maintaining an upright patient position.

The project focuses on assessing the clinical viability of helium ion therapy, which researchers believe could offer improved precision in tumor targeting compared to traditional proton therapy. By utilizing a compact architecture, the initiative aims to reduce the physical footprint typically required for particle therapy facilities.

"This collaboration allows for the exploration of how upright positioning and multi-ion capability might enhance therapeutic outcomes," said a representative for the research team. The collaboration will take place in Houston, utilizing the clinical resources of MD Anderson to test the system's performance and clinical workflows.

The initiative represents a broader industry trend toward downsizing complex medical hardware to improve accessibility. The initial phase will focus on gathering data on the dual-modality delivery system, with potential implications for future cancer treatment protocols.